Pde9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases

Abstract

The present invention relates to PDE9 inhibitors and their use for treatment of benign prostate hyperplasia and sickle cell disease.

1 . A compound selected from the group consisting of 3-(4-fluorophenyl)-6-((3-(pyridin-4-yloxy)azetidin-1-yl)methyl)imidazo[1,5-a]pyrazin-8(7H)-one (P1), 6-[3-(pyridin-3-yloxy)-azetidin-1-ylmethyl]-3-(tetrahydro-pyran-4-yl)-7H-imidazo[1,5-a]pyrazin-8-one (P2), and 2-[3-(4-fluoro-phenoxy)-azetidin-1-ylmethyl]-7-(tetrahydro-pyran-4-yl)-3H-imidazo[5,1-][1,2,4]triazine-one (P4). 
     
     
         2 . The compound of  claim 1 , wherein the compound is 3-(4-fluorophenyl)-6-((3-(pyridin-4-yloxy)azetidin-1-yl)methyl)imidazo[1,5-a]pyrazin-8(7H)-one (P1), or 6-[3-(pyridin-3-yloxy)-azetidin-1-ylmethyl]-3-(tetrahydro-pyran-4-yl)-7H-imidazo[1,5-a]pyrazin-8-one (P2). 
     
     
         3 . The compound of  claim 1 , wherein the compound is 2-[3-(4-fluoro-phenoxy) azetidin-1-ylmethyl]-7-(tetrahydro-pyran-4-yl)-3H-imidazo[5,1-f][1,2,4]triazin-4-one (P4). 
     
     
         4 . A pharmaceutical composition comprising a therapeutically effective amount of any of the compounds in  claim 1 , and one or more pharmaceutically acceptable carriers, diluents or excipients. 
     
     
         5 . The pharmaceutical composition of  claim 4 , wherein the compound is 3-(4-fluorophenyl)-6-((3-(pyridin-4-yloxy)azetidin-1-yl)methyl)imidazo[1,5-a]pyrazin-8(7H)-one (P1), or 6-[3-(pyridin-3-yloxy)-azetidin-1-ylmethyl]-3-(tetrahydro-pyran-4-yl)-7H-imidazo[1,5-a]pyrazin-8-one (P2). 
     
     
         6 . The pharmaceutical composition of  claim 4 , wherein the compound is 2-[3-(4-fluoro-phenoxy)-azetidin-1-ylmethyl]-7-(tetrahydro-pyran-4-yl)-3H-imidazo[5,1-f][1,2,4]triazin-4-one (P4). 
     
     
         7 . A method of treating a subject from benign prostate hyperplasia or sickle cell disease comprising administering to the subject a therapeutically effective amount of any one the compounds in  claim 1 . 
     
     
         8 . The method of  claim 7 , wherein the compound is 3-(4-fluorophenyl)-6-((3-(pyridin-4-yloxy)azetidin-1-yl)methyl)imidazo[1,5-a]pyrazin-8(7H)-one (P1) or 6-[3-(pyridin-3-yloxy)-azetidin-1-ylmethyl]-3-(tetrahydro-pyran-4-yl)-7H-imidazo[1,5-a]pyrazin-8-one (P2). 
     
     
         9 . The method of  claim 7 , wherein the compound is 2-[3-(4-fluoro-phenoxy)-azetidin-i-ylmethyl]-7-(tetrahydro-pyran-4-yl)-3H-imidazo[5, 1-f][1,2,4]triazin-4-one (P4). 
     
     
         10 . A method of treating a subject from benign prostate hyperplasia or sickle cell disease comprising administering to the subject the pharmaceutical composition of  claim 5  or  claim 6 . 
     
     
         11 . A method of treating a subject from urinary tract dysfunctional epithelium or erectile dysfunction, comprising administering to the subject a therapeutically effective amount of a compound selected from the group consisting of 3-(4-fluorophenyl)-6-((3-(pyridin-4-yloxy)azetidin-1-yl)methyl)imidazo[1,5-a]pyrazin-8(7H)-one (P1), 6-[3-(pyridin-3-yloxy)-azetidin-1-ylmethyl]-3-(tetrahydro-pyran-4-yl)-7H-imidazo[1,5-a]pyrazin-8-one (P2), (3S,4S)-6-(4-methyl-1-pyrimidin-2-ylmethyl-pyrrolidin-3-yl) 3-(tetrahydro-pyran-4-yl)-7H-imidazo[1,5-a]pyrazin-8-one (P3, enantioner 1), (3R,4R)-6-(4-methyl-1-pyrimidin-2-ylmethyl-pyrrolidin-3-yl)-3-(tetrahydro-pyran-4-yl)-7-imidazo[1,5-a]pyrazin-8-one (P3, enantiomer 2), and 2-[3-(4-fluoro-phenoxy)-azetidin-1-ylmethyl]-7-(tetrahydro-pyran-4-yl)-3H-imidazo[5,1-f][1,2,4]triazin-4-one (P4).